PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Dupilumab - Prurigo nodularis

PAD Profile : Dupilumab - Prurigo nodularis

Brand Names Include :
Dupixent

Traffic Light Status

Status 1 of 1.

Status :
Non Formulary
Formulations :
  • Subcutaneous injection (sc)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD2
Comments :
No comments returned.

Guidelines

No guidelines returned.

Other Drugs

No drugs returned.

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
03 April 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed that dupilumab for Prurigo Nodularis will be given a NON-FORMULARY traffic light status following publication of NICE TA955

Dupilumab is not recommended, by NICE, within its marketing authorisation, for treating this indication

Associated BNF Codes

13. Skin
13.05.03. Drugs affecting the immune response
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More